Updates

Ewing Sarcoma Center

 Clinical Trials for patients with Ewing sarcoma

Texas Children’s Cancer Center offers the following clinical trials for patients with Ewing sarcoma. For more detailed information such as current enrollment status and eligibility criteria for these trials, referring physicians may call 1-800-226-2379 (1-800-CANCER9). Families may contact us toll-free at 1-844-394-6471 (1-844-EWINGS1).

Also provided here is a Clinical Trials Search Tool, built in collaboration with Institute for Clinical and Translational Research, Baylor College of Medicine, that allows users to search for specific clinical trials anywhere in the United States.

Study ID Study Title Principal Investigator
AEWS1221 Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metatastic Ewing Dr. Nino Rainusso
SGT-53 A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children with Refractory or Recurrent Solid Tumors Dr. Jodi Muscal
RXDX-101 A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions Dr. Jennifer Foster
Olaratumab A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors Dr. Jodi Muscal
CUDC-907 Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Dr. Jodi Muscal
ADVL1212 A Phase 1 Study of Crizotinib (IND#105573) in Combination With Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma  Dr. Jodi Muscal
ADVL1411 A Phase I/II Study of BMN 673 (IND#121510), an Oral Poly (ADP-Ribose) Polymerase Inhibitor, plus Temozolomide in Children with Refractory or Recurrent Malignancies Enrollment criteria Dr. Jodi Muscal
ADVL1412 A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab Dr. Karen Rabin
ADVL1416 A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors Dr. Jodi Muscal
Pembrolizumab A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children With Recurrent, Progressive or, Refractory High-Grade Gliomas (HGG), DIPGs and Hypermutated Brain Tumors. Dr. Patricia Baxter
ADVL1515 A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors Dr. Jodi Muscal
ADVL1513 A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma Dr. Jodi Muscal
ADVL1322 Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Dr. Mehmet Okcu
HEROS Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma Dr. Nabil Ahmed
HEROS 3.0 HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination with Checkpoint Blockade in Patients With Advanced Sarcoma (HEROS 3.0) Dr. Shoba Navai
Dr. Meenakshi Hegde
TK216 TK216 in Patients With Relapsed or Refractory Ewing Sarcoma Dr. Jodi Muscal

Ranked #6 in Cancer

Proud to be ranked one of the best children’s cancer centers in the country by U.S. News & World Report for seven consecutive years.

See Rankings

Related Departments